These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 38349383)

  • 21. Noninferiority of Preservative-free Versus BAK-preserved Latanoprost-timolol Fixed Combination Eye Drops in Patients With Open-angle Glaucoma or Ocular Hypertension.
    Aptel F; Pfeiffer N; Schmickler S; Clarke J; Lavín-Dapena C; Moreno-Montañés J; Żarnowski T; Csutak A; Jugaste T; Volksone L; Astakhov YS; Coupier L; Nordmann JP; Stalmans I;
    J Glaucoma; 2019 Jun; 28(6):498-506. PubMed ID: 31166287
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Poly(2-hydroxyethyl methacrylate)/β-cyclodextrin-hyaluronan contact lens with tear protein adsorption resistance and sustained drug delivery for ophthalmic diseases.
    Li R; Guan X; Lin X; Guan P; Zhang X; Rao Z; Du L; Zhao J; Rong J; Zhao J
    Acta Biomater; 2020 Jul; 110():105-118. PubMed ID: 32339710
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Multiple drug delivery from the drug-implants-laden silicone contact lens: Addressing the issue of burst drug release.
    Desai AR; Maulvi FA; Desai DM; Shukla MR; Ranch KM; Vyas BA; Shah SA; Sandeman S; Shah DO
    Mater Sci Eng C Mater Biol Appl; 2020 Jul; 112():110885. PubMed ID: 32409042
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sustained Delivery of Timolol Using Nanostructured Lipid Carriers-Laden Soft Contact Lenses.
    Tian C; Zeng L; Tang L; Yu J; Ren M
    AAPS PharmSciTech; 2021 Aug; 22(6):212. PubMed ID: 34378099
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Nanomedicine for glaucoma: liposomes provide sustained release of latanoprost in the eye.
    Natarajan JV; Ang M; Darwitan A; Chattopadhyay S; Wong TT; Venkatraman SS
    Int J Nanomedicine; 2012; 7():123-31. PubMed ID: 22275828
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [In vitro evaluation for corneal damages by anti-glaucoma combination eye drops using human corneal epithelial cell (HCE-T)].
    Nagai N; Murao T; Oe K; Ito Y; Okamoto N; Shimomura Y
    Yakugaku Zasshi; 2011; 131(6):985-91. PubMed ID: 21628988
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Fixed-combination brimonidine-timolol versus latanoprost in glaucoma and ocular hypertension: a 12-week, randomized, comparison study.
    Katz LJ; Rauchman SH; Cottingham AJ; Simmons ST; Williams JM; Schiffman RM; Hollander DA
    Curr Med Res Opin; 2012 May; 28(5):781-8. PubMed ID: 22458918
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Preserved Versus Preservative-Free Latanoprost for the Treatment of Glaucoma and Ocular Hypertension: A Post Hoc Pooled Analysis.
    Harasymowycz P; Hutnik C; Rouland JF; Negrete FJM; Economou MA; Denis P; Baudouin C
    Adv Ther; 2021 Jun; 38(6):3019-3031. PubMed ID: 33891269
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Development of Timolol-Loaded Galactosylated Chitosan Nanoparticles and Evaluation of Their Potential for Ocular Drug Delivery.
    Zhao R; Li J; Wang J; Yin Z; Zhu Y; Liu W
    AAPS PharmSciTech; 2017 May; 18(4):997-1008. PubMed ID: 28101726
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Diquafosol Delivery from Silicone Hydrogel Contact Lenses: Improved Effect on Tear Secretion.
    Dominguez-Godinez C; Carracedo G; Pintor J
    J Ocul Pharmacol Ther; 2018; 34(1-2):170-176. PubMed ID: 28700254
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lollipop-Inspired Multilayered Drug Delivery Hydrogel for Dual Effective, Long-Term, and NIR-Defined Glaucoma Treatment.
    Wang F; Song Y; Huang J; Wu B; Wang Y; Pang Y; Zhang W; Zhu Z; Ma F; Wang X; Zhang X
    Macromol Biosci; 2021 Nov; 21(11):e2100202. PubMed ID: 34405963
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Human experience and efficacy of omidenepag isopropyl (Eybelis®; Omlonti®): Discovery to approval of the novel non-prostaglandin EP2-receptor-selective agonist ocular hypotensive drug.
    Sharif NA
    Curr Opin Pharmacol; 2024 Feb; 74():102426. PubMed ID: 38168596
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Latanoprost : an update of its use in glaucoma and ocular hypertension.
    Perry CM; McGavin JK; Culy CR; Ibbotson T
    Drugs Aging; 2003; 20(8):597-630. PubMed ID: 12795627
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Intraocular pressure-lowering effect of omidenepag isopropyl in latanoprost non-/low-responder patients with primary open-angle glaucoma or ocular hypertension: the FUJI study.
    Aihara M; Ropo A; Lu F; Kawata H; Iwata A; Odani-Kawabata N; Shams N
    Jpn J Ophthalmol; 2020 Jul; 64(4):398-406. PubMed ID: 32572719
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The additive intraocular pressure-lowering effect of latanoprost 0.005% daily once and pilocarpine 2% t.i.d. in patients with open-angle glaucoma or ocular hypertension. a 6-month, randomized, multicenter study. German Latanoprost Study Group.
    Diestelhorst M
    Graefes Arch Clin Exp Ophthalmol; 2000 May; 238(5):433-9. PubMed ID: 10901475
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and safety of the fixed combinations latanoprost/timolol versus dorzolamide/timolol in patients with elevated intraocular pressure.
    Shin DH; Feldman RM; Sheu WP;
    Ophthalmology; 2004 Feb; 111(2):276-82. PubMed ID: 15019375
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The Effect of Therapeutic IOP-lowering Interventions on the 24-hour Ocular Dimensional Profile Recorded With a Sensing Contact Lens.
    Cutolo CA; De Moraes CG; Liebmann JM; Mansouri K; Traverso CE; Ritch R;
    J Glaucoma; 2019 Mar; 28(3):252-257. PubMed ID: 30640804
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Timolol + latanoprost: new preparation. Last-resort eye drops.
    Prescrire Int; 2003 Oct; 12(67):173-4. PubMed ID: 14619889
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A 12-week, randomized, double-masked study of fixed combination latanoprost/timolol versus latanoprost or timolol monotherapy.
    Palmberg P; Kim EE; Kwok KK; Tressler CS;
    Eur J Ophthalmol; 2010; 20(4):708-18. PubMed ID: 20099236
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of latanoprost and timolol in pediatric glaucoma: a phase 3, 12-week, randomized, double-masked multicenter study.
    Maeda-Chubachi T; Chi-Burris K; Simons BD; Freedman SF; Khaw PT; Wirostko B; Yan E;
    Ophthalmology; 2011 Oct; 118(10):2014-21. PubMed ID: 21680022
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.